Novo Nordisk, a global pharmaceutical company, has launched oral semaglutide in India to treat Type 2 diabetes. The drug was launched last year and has shown promising results in managing blood sugar levels and weight loss. Oral semaglutide is the first-of-its-kind oral GLP-1 receptor agonist that enables patients to conveniently administer the medication at home. This launch aims to provide a more convenient and effective treatment option for patients with Type 2 diabetes in India.